Recognition places Lumea among elite global winners including Medtronic and Thermo Fisher Scientific in one of digital health’s most competitive annual programs

Recent pathogens illustrate need for improved situational awareness capabilities, such as those provided by the Co-Dx PCR point-of-care platform

Funds will fuel sales team expansion and broader market access, advancing the company’s leadership in Implantable Tibial Neuromodulation (ITNM) for the treatment of urgency urinary incontinence (UUI)

351-patient trial completion marks a key milestone for the Celeste® program; topline data to be presented May 26 in Phoenix

FDA stated that the “proposed data may be capable of supporting the submission and review of an [NDA] under the accelerated approval pathway” for CNM-Au8 based on neurofilament light (NfL) biomarker data

VOXZOGO is the only approved treatment for children with achondroplasia starting at birth, with over 10 years of clinical research demonstrating the long-term benefit on complications associated with achondroplasia

Two ARUP Medical Directors Receive Career Achievement Awards

As gaps in early detection persist, a 45-second voice analysis offers a new way to identify signals of stress, anxiety, and depression during Mental Health Awareness Month